250+ investors that invest in your industry and stage
Marketplace
Gaming
Community
Proptech
Biotech
Impact
Health Care
FinTech
Energy
Google
Artificial intelligence
EdTech
Consumer
Sustainability
Climate
Venture Capital
Real Estate
Finance
Retail
Web3
Hardware
Video Games
Publishing
Digital Media
Beauty
Education
Music
B2B
Android
Payments
Organic Food
Infrastructure
Food and Beverage
Financial Services
Franchise
Photography
Clean Energy
Big Data
Construction
Biotechnology
Cannabis
Enterprise Software
Fitness
Sports
Travel
Recruiting
Manufacturing
Platforms
Mobile Advertising
Email
Hospitality
Internet
Automotive
Crowdfunding
Local
Social
Medical Device
Wine And Spirits
Social Network
CleanTech
Mobile Apps
Transportation
InsurTech
Social Media
Enterprise
Wellness
LGBT
Medical
Art
Legal
Mobile
eSports
Fashion
Oil and Gas
Non Profit
Theatre
Film
Life Science
SaaS
Renewable Energy
Sporting Goods
Celebrity
Restaurants
Social Impact
Software
Cryptocurrency
Facebook
Machine Learning
Agriculture (agtech)
Media (entertainment)
Blockchain
United Kingdom
United States
Germany
India
Australia
Canada
New Zealand
South Korea
Ireland
Saudi Arabia
Brazil
Armenia
Qatar
Asia
Sri Lanka
Europe
Spain
South Africa
Vietnam
Japan
China
Singapore
Middle East
LATAM
Belgium
Africa
Hungary
Oceania
Faroe Islands
Belarus
Indonesia
Bahrain
Gibraltar
Liberia
Kuwait
France
Philippines
Barbados
Greece
Malaysia
Morocco
Belize
Hong Kong
Peru
Nicaragua
Algeria
Ghana
Malta
Liechtenstein
Mexico
Denmark
Lithuania
Finland
Estonia
Lebanon
Jersey
Croatia
Myanmar
Mali
Israel
Bermuda
Chile
Panama
Costa Rica
Italy
Georgia
Mauritius
Ecuador
Bulgaria
Norway
Ukraine
Czech Republic
Turkey
Serbia
Ethiopia
Egypt
Sierra Leone
Rwanda
Venezuela
Dominican Republic
Sweden
Senegal
Bahamas
Namibia
Azerbaijan
Iceland
Tajikistan
Puerto Rico
Portugal
Nigeria
Slovenia
Iraq
United Arab Emirates
Uganda
Jamaica
Honduras
Taiwan
Bolivia
Isle of Man
Togo
Russian Federation
Mozambique
Luxembourg
Tanzania
Zimbabwe
San Marino
Uruguay
Albania
Pakistan
Poland
El Salvador
Grenada
Jordan
Thailand
Romania
Tunisia
Zambia
Argentina
Uzbekistan
Kazakhstan
Bangladesh
Kenya
Cambodia
Cayman Islands
Cyprus
Oman
Latvia
Austria
Cameroon
Switzerland
Colombia
Guatemala
Seychelles
Marshall Islands
Angel investors
VC Funds
All investors
Download Find emails Save list

Top 15 Life Science VC (Venture Capital) Funds in Oceania in May 2026

A list of 15 VC (Venture Capital) funds that invest in Life science startups based in Oceania. We rank investors based on the number of investments they made in Life science companies from Oceania. We update this investor list every month.

Top 15 Life Science VC (Venture Capital) Funds in Oceania in May 2026

Investor Life Science Oceania investments
Main Sequence Ventures 2
Alium Capital 1
Catalio Capital Management 1
The March Group 1
Possible Ventures 1
Churchill Asset Management 1
Accelerating Commercialisation - AusIndustry 1
OneVentures 1
Uniseed Ventures 1
Medical Research Commercialisation Fund (MRCF) 1
Tin Alley Ventures 1
Skalata 1
Breakthrough Victoria 1
AbbVie Biotech Ventures 1
Uniseed 1

Reach every investor

Get a list of investors who already back your industry, stage, and country. Emails & phones included.

Find investors — It's Free!
Investor list
Main Sequence Ventures
VC Fund · Sydney, New South Wales, Australia

We work with inventors who are building something hard from their unique expertise in science. These inventors are building the industries that will thrive for the decades to come. We have a unique working model to accelerate a company's pathway to scale.

Show more...

Investment focus

  • Software, Artificial Intelligence, Manufacturing
  • Seed, Series A, Series B
  • Australia, United States, Philippines

Portfolio highlights

  • Morse Micro — Morse Micro is a fast-growing wireless integrated circuit solutions company that is reinventing Wi-Fi for the Internet of Things (IoT). The company was founded by Wi-Fi pioneers and innovators, Michael De Nil and Andrew Terry, joined by the original Wi-Fi inventor Prof. Neil Weste and wireless industry veterans, whose teams designed Wi-Fi chipsinto billions of smartphones. Headquartered in Australia with offices in China and the U.S., Morse Micro’s strong and diverse system team, portfolio of IP and patents, enables Wi-Fi HaLow connectivity across the complete IoT ecosystem, from surveillance systems and access control to industrial automation and mobile devices, allowing connected devices to reach farther. www.morsemicro.com
  • Prospection — Helping pharmaceutical brand teams unlock patient-centric intelligence to drive better patient care outcomes and capture market share opportunities.
  • QuintessenceLabs — Quantum cyberattacks can break current encryption in minutes! Get protected with QuintessenceLabs quantum key distribution, generation, and management.
Show all investments...

Alium Capital
VC Fund · Sydney, New South Wales, Australia

Alium Capital focuses on listed and unlisted technology investments to generate out-sized returns. The company invests in technology, innovation, and early-stage businesses, all the way through to publicly listed assets. It specializes in the fields of finance, investing, innovation, and capital.Alium Capital was founded in 2016 andheadquartered in Sydney, New South Wales.

Show more...

Investment focus

  • Software, Financial Services, Apps
  • Series A, Series B, Seed
  • Australia, United States, Singapore

Portfolio highlights

  • Beforepay — Beforepay understands that traditional pay cycles are a form of financial stress. So we set out to find a better way, giving Australians the control and confidence that comes with managing your own money, on your terms.That’s why we created Pay On Demand™ - a service that allows you to access the money you have earned at work, when you choose todo so. After all, it is yours!The app also automatically predicts when your bills are due, shows you how much is OK for you to spend, and automatically creates budgets for you, effortlessly.
  • Academy Xi — At Academy Xi, we help APAC's largest and most sophisticated organisations optimise performance with concise, actionable training solutions.
  • DesignCrowd — Crowdsourced logo, freelance graphic and web design at DesignCrowd. 1,328,201 freelance designers compete to create amazing designs for your business. Start Today!
Show all investments...

Catalio Capital Management
VC Fund · Baltimore, Maryland, United States

Catalio Capital Management was created by George Petrocheilos and Dr. Jacob Vogelstein to invest in breakthrough biomedical technology companies created or referred by Catalio Capital Management, an elite group of world-renowned, serial scientist-entrepreneurs.

Show more...

Investment focus

  • Biotechnology, Health Care, Life Science
  • Series A, Series B, Funding Round
  • United States, Switzerland, Israel

Portfolio highlights

  • Ensoma — Ensoma is expanding the reach of the curative power of genomic medicine by pioneering a next-generation in vivo approach using its Engenious™ vectors. Ensoma’s vectors are designed to deliver a diverse range of gene modification technologies without the need for stem cell collection or prior myeloablative conditioning (e.g., chemotherapy). As aresult, Ensoma’s therapies can be delivered as a single injection in a diverse range of settings, including outpatient and settings where access to sophisticated healthcare systems may be limited.
  • OSPRI — Multiplex qPCR reagent kits for assay development, biomarker discovery, and translational research. 120+ configurations across a broad range of research areas. Extraction-free. Customizable. For Research Use Only.
  • Leo Cancer Care — Leo Cancer Care is the more human way to treat cancer, built on research from across the globe showing the benefits of upright patient positioning. Combined with a shift from machine rotation to patient rotation, Leo Cancer Care is set to change the face of Radiation Therapy for good. Finding a bett
Show all investments...

The March Group
VC Fund · Davis, California, United States

A venture capital fund platform committed to supporting and investing in entrepreneurs and companies developing and bringing exponential technologies to food, health and sustainability. March's investment strategy involves becoming recognized as the leading investor in critical and transformative technology solutions, and aims to achieve thisby investing into companies and funds that focus on developing core intellectual property around game-changing sustainable solutions that are aligned with globally relevant sustainability trends and benefits.

Show more...

Investment focus

  • SaaS, Energy, Retail
  • Seed, Series A, Series C
  • United States

Portfolio highlights

  • Digestiva — We amplifye Protein.
  • EvodiaBio — Mirroring nature with pioneering bioscience for natural flavors
  • Number 8 bio — Number 8 Bio is a scientist-led start-up in Sydney that makes scalable and affordable enteric methane mitigation feed additives for livestock. We have a unique approach to managing rumen energy flows and animal productivity when methane is decreased, and we aim to give farmers a healthy ROI when using the additives.
Show all investments...

Possible Ventures
VC Fund · Munich, Bayern, Germany

Possible Ventures backs ambitious teams building frontier technology to positively impact society. We invest globally in the early stages, actively supporting founders via our collective of global entrepreneurs.

Show more...

Investment focus

  • Software, Biotechnology, Information Technology
  • Seed, Pre-Seed, Series A
  • Germany, Australia, United States

Portfolio highlights

  • Telura — Telura is a deep-tech business that uses next-generation drilling to enable geothermal energy everywhere. Telura creates electric impulse drilling technology, which breaks rock from within using high-voltage pulses.
  • EntryLevel — Learn in an affordable, peer-driven environment over 6 weeks with mentors from top companies across the world such as Atlassian, Wise and more.
  • VSPARTICLE — VSPARTICLE develops nanoparticle generators for various applications such as sensors, batteries, catalysis, solar cells, healthcare, additive manufacturing, nano safety, and more. It also enables research and industry to generate new materials at the push of a button.They specialize in nanoparticle production and integration. The technologyspeeds up the developments of customers by producing the desired nanoparticles on location and integrate them directly in the final product. VSPARTICLE was founded in 2014 and is headquartered in Delft, The Netherlands.
Show all investments...

Churchill Asset Management
VC Fund · New York, New York, United States

Churchill is a leading capital provider for private equity-owned, middle market companies. We provide first lien, unitranche, second lien and mezzanine debt, in addition to equity co-investments, secondary solutions and private equity fund commitments.

Show more...

Investment focus

  • Health Care, Pet, Dental
  • Debt Financing, Private Equity
  • United States

Portfolio highlights

  • Proto Axiom — Early-stage funding to growth capital, we guide scientific breakthroughs from proof-of-concept to commercial success. Our hands-on approach to support Australian research is a first-in-country model.
  • Mosaic Dental Collective — Mosaic Dental Collective provides administrative and business operations support to dental practices. They are a multi-specialty group where doctors make decisions and are supported by an experienced professional management team.
  • Heartland Veterinary Partners — Heartland Veterinary Partners purchases practices, providing operational support for payroll, HR, marketing, and more. Veterinarians can focus on patient care.
Show all investments...

Accelerating Commercialisation - AusIndustry
VC Fund · Canberra, Australian Capital Territory, Australia

A grant program offered by AusIndustry as part of the Australian Government’s National Innovation and Science Agenda

Show more...

Investment focus

  • Software, Mining, Hardware
  • Grant, Pre-Seed
  • Australia

Portfolio highlights

  • Neuromersiv — Combining Virtual Reality, haptics and functional electrical stimulation, Neuromersiv is revolutionising brain rehabilitation therapy.Using a proprietary wearable device paired with a VR headset, Neuromersiv provides an engaging, immersive therapy experience in which patients perform gamified tasks ranging from picking up a toothbrush to climbingEverest! This unique approach increases dopamine activity in the brain, enhancing neuroplasticity, which is the brain’s ability to form new neural connections. Early trials of Neuromersiv technology have demonstrated 3x better outcomes as compared to traditional rehabilitation therapy resulting in faster independence and reduced care costs.
  • Tiny Bright Things — Melbourne-based company Tiny Bright Things was cofounded in 2020 by long-time research collaborators Ray Dagastine and Chris Bolton. We invented Halo microscopy to transform the way researchers and manufacturers look at small or transparent things. This helps manufacturers in areas like agrichemicals and pharmaceuticals (where the size and shape ofpowders are critical) and researchers at every stage of discovery— particularly in nanotechnology (where samples are especially tiny) and life sciences (where samples are often also transparent).
Show all investments...

OneVentures
VC Fund · Sydney, New South Wales, Australia

OneVentures is one of Australia’s leading venture capital firms, with over $330M in funds under management. But they do more than invest. They take companies to that all important next stage, by actively shaping their future. They apply their years of international experience, operational and executional expertise to accelerate the growth of theirportfolio companies. A global growth focus drives their investment selection with their current portfolio including companies with truly innovative products tackling multi-billion-dollar problems, from needle-free vaccinations to virtual communications to adaptive e-learning.

Show more...

Investment focus

  • Software, Health Care, Biotechnology
  • Series A, Debt Financing, Funding Round
  • Australia, United States, Israel

Portfolio highlights

  • Hometime — At Hometime, we provide Airbnb property management solutions for homeowners and rental management business owners that help them scale and earn more.
  • StrongDM — Manage access to any server, database, or Kubernetes instance in minutes. Fully auditable, replayable, secure, and drag-and-drop easy.
  • Employment Hero — Recruitment, HR, Payroll & Benefits in one place - designed for small & medium businesses to be efficient, compliant & cost-Effective. Book a demo today!
Show all investments...

Uniseed Ventures
VC Fund · Brisbane, Queensland, Australia

Uniseed was established in October 2000 as a $20 million joint venture between the University of Melbourne (UM) and the University of Queensland (UQ). This proof of concept fund (Fund-1) operated with significant input and support from the commercialization offices of the two universities (UniQuest and Melbourne Ventures Limited), with staff ofthese organizations making up the majority of the Investment Committee and leading due diligence and management of most investment opportunities. Over 20 investments, typically of $250,000 - $500,000 were made from this fund.A new $40 million venture fund (Fund-2) ran from 2005-15, with the addition of a third leading university, the University of New South Wales, and a major private institutional investor, the Westscheme superannuation fund. The founding universities (UQ & UM) also committed further funds. Australian Super took over Westscheme's essets and commitments in July 2011.With the start of Fund-2, an independent management team was established, consisting of the CEO and three Investment Managers; one at each university catchment. The Investment Committee was restructured, with dedicated committees established for biotechnology or other technologies. The nominal investment limit was increased to $2.5 million to allow participation in follow-on funding rounds so as to preserve Uniseed's equity position.On 1 November 2015, Uniseed started its third and largest fund (Fund-3) with the addition of the University of Sydney and the CSIRO to the Universities of Queensland, Melbourne and NSW. This followed three high profile exits in the preceding 14 months (Fibrotech; Spinifex & Hatchtech). Each of the five partners committed $10 million over 10 years to the new fund (total fund $50 million).Uniseed’s partner research organisations spent nearly $4 billion on research, making up over 40% of the total research spend at 67 research organisations in Australia. Together, these organisations accounted for nearly 500 invention disclosures (34% of total) and 500 new registered IP rights filed (45% of total) over the same period(2013 National Survey of Research Commercialisation). Unlike private venture capital funds, Uniseed is dedicated to the needs of its research partners, and committed to servicing them consistently over the long term, irrespective of the short term conditions in external capital markets. It works in very close partnership with the research partner commercialisation companies and staff, providing a valuable adjunct to the capabilities these companies and staff provide. They in turn provide a best-practice commercialisation service tailored to their respective organisations. These companies are able to leverage to great effect the scale of operation and expertise of the Uniseed network.The fund is run with commercial discipline, ensuring independence and financial rigor in its investment decision-making processes. Success is measured by a balance of return on investment (including the flow of funds for research to further the commercialisation of intellectual property generated within the research partner catchments), the establishment of viable start-up companies, the generation of research income for research partners and the improvement of partner commercialisation processes.

Show more...

Investment focus

  • Biotechnology, Health Care, Manufacturing
  • Series A, Seed, Funding Round
  • Australia, United States, United Kingdom

Portfolio highlights

  • BioScout — Welcome to BioScout, your partner in revolutionizing the agriculture industry with cutting-edge automated disease detection technology for crop growers and viticulture.
  • Ferronova — Ferronova is a medical device company that offers imaging and surgery products.
  • Morse Micro — Morse Micro is a fast-growing wireless integrated circuit solutions company that is reinventing Wi-Fi for the Internet of Things (IoT). The company was founded by Wi-Fi pioneers and innovators, Michael De Nil and Andrew Terry, joined by the original Wi-Fi inventor Prof. Neil Weste and wireless industry veterans, whose teams designed Wi-Fi chipsinto billions of smartphones. Headquartered in Australia with offices in China and the U.S., Morse Micro’s strong and diverse system team, portfolio of IP and patents, enables Wi-Fi HaLow connectivity across the complete IoT ecosystem, from surveillance systems and access control to industrial automation and mobile devices, allowing connected devices to reach farther. www.morsemicro.com
Show all investments...

Medical Research Commercialisation Fund (MRCF)
VC Fund · Melbourne, Victoria, Australia

Medical Research Commercialisation Fund (MRCF) provides dedicated, investment funding to support the commercialisation of early-stage medical research discoveries that originate from its member institutes. The collaborative nature of the MRCF seeks to foster best practice in the commercialisation of medical innovations.

Show more...

Investment focus

  • Biotechnology, Health Care, Medical
  • Series A, Seed, Series B
  • Australia, United States, United Kingdom

Portfolio highlights

  • Glyscend Therapeutics — Glyscend develops a revolutionary approach to treating type 2 diabetes. The company began with the insight that bariatric surgery can lead to the immediate remission of the disease, and has since been engaged in the development of a non-invasive approach which will act on the same mechanism as surgery but fit within the current care pathway. Thecompany's technology is an orally ingestible intestinal coating that prevents the stimulation of duodenal mucosa and inhibits key neurohormonal pathways in the proximal gut. Glyscend is devoted to providing patients with an effective strategy to keep glucose levels under control and eliminate potential side effects like weight gain and hypoglycemia. Meanwhile, the company aims to provide endocrinologists and primary care physicians with the innovative tools they need to treat the disease instead of merely managing it. It was founded in 2014 by co-founders Ashish Nimgaonkar, Michael Parlato, and Pratik Patel.
  • Currus Biologics — Currus Biologics is a biotechnology company that develop CAR-T cell therapies for the treatment of solid tumour cancers.
  • Azura Ophthalmics — Azura Ophthalmics is a clinical-stage company that develops an innovative portfolio of compounds to advance treatments for MGD, the leading cause of DED. By targeting the root cause of MGD, Azura brings the promise of improved health and well-being to millions of people worldwide who suffer from MGD and other ocular surface diseases where treatmentoptions are currently lacking. Azura is underpinned by an experienced management team with an established track record of successfully developing and commercializing novel treatments for ocular surface diseases. The company headquartered in Tel Aviv-Yafo, Israel with operations in Australia and the U.S.
Show all investments...

Tin Alley Ventures
VC Fund · Carlton, Victoria, Australia

Tin Alley Ventures collaborates with companies and researchers in the University of Melbourne's ecosystem to invest in & support world-changing businesses.

Show more...

Investment focus

  • Medical, Health Care, Therapeutics
  • Pre-Seed
  • Australia

Portfolio highlights

  • Cell Bauhaus — Cell Bauhaus uses mathematical and computer modeling to understand, predict, and modify living cell behavior, aiming to expedite sustainable solutions to humanity's pressing issues.
  • Remagine Labs — Remagine Labs is revolutionizing healthcare with a bluetooth-connected, wearable electro-pharmaceutical that provide patient-centered care and consistent drug administration, giving healthcare customers peace of mind all over the world.
  • Psychae Therapeutics — Psychae Therapeutics develop innovative pharmaceutical grade DMT-based medicines and therapies aiming to transform the lives of those facing some of the most prolific and insidious mental illnesses
Show all investments...

Skalata
VC Fund · Melbourne, Victoria, Australia

Giving Australian founders access to the education, capital and networks needed to build significant, sustainable, global businesses of the future.

Show more...

Investment focus

  • Software, Information Technology, Apps
  • Pre-Seed, Seed
  • Australia, United States, United Kingdom

Portfolio highlights

  • TALY — TALY is a platform that is designed to find, manage and retain employees from both perfromance and personality for business development.
  • Viewa — Viewa is an augmented reality(AR) content publishing platform that brings print media such as magazines to life in 3D.
  • Termina — Termina operates as an energy tech startup.
Show all investments...

Breakthrough Victoria
VC Fund · Melbourne, Victoria, Australia

The Breakthrough Victoria Fund is a $2 billion investment by the Victorian Government to drive investment in research and innovation.

Show more...

Investment focus

  • Manufacturing, Health Care, Software
  • Funding Round, Series A, Seed
  • Australia, United States, Philippines

Portfolio highlights

  • DeepDerm — DeepDerm is developing AI-enabled cameras that detect skin cancer without the need for painful biopsies.
  • InnovaIVF — InnovaIVF transforms the reproductive technology landscape with innovative solutions.
  • Mental Jam — We are a games studio dedicated to ​creating impactful experiences that ​explore mental health.
Show all investments...

AbbVie Biotech Ventures
VC Fund · North Chicago, Illinois, United States

AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. Togetherwith its wholly-owned subsidiary, Pharmacyclics, AbbVie employs ~29,000 people worldwide and markets medicines in more than 175 countries.

Show more...

Investment focus

  • Biotechnology, Health Care, Therapeutics
  • Series A, Series B, Series C
  • United States, China, Italy

Portfolio highlights

  • Mozart Therapeutics — The company intended to focus on developing novel immune engagers.
  • Quanta Therapeutics — Quanta is a biotechnology company uncovering novel cancer therapeutic candidates using allosteric modulation to target driver oncogenes. The company was founded in 2018 and is based in San Francisco, CA.
  • DISCO Pharmaceuticals — DISCO Pharmaceuticals is a firm that specializes in large-scale surfaceome unlocking of cancer cells.
Show all investments...

Uniseed
VC Fund · Brisbane, Queensland, Australia

Uniseed was established in October 2000 as a $20 million joint venture between the University of Melbourne (UM) and the University of Queensland (UQ). This proof of concept fund (Fund-1) operated with significant input and support from the commercialization offices of the two universities (UniQuest and Melbourne Ventures Limited), with staff ofthese organizations making up the majority of the Investment Committee and leading due diligence and management of most investment opportunities. Over 20 investments, typically of $250,000 - $500,000 were made from this fund.A new $40 million venture fund (Fund-2) ran from 2005-15, with the addition of a third leading university, the University of New South Wales, and a major private institutional investor, the Westscheme superannuation fund. The founding universities (UQ & UM) also committed further funds. Australian Super took over Westscheme's essets and commitments in July 2011.With the start of Fund-2, an independent management team was established, consisting of the CEO and three Investment Managers; one at each university catchment. The Investment Committee was restructured, with dedicated committees established for biotechnology or other technologies. The nominal investment limit was increased to $2.5 million to allow participation in follow-on funding rounds so as to preserve Uniseed's equity position.On 1 November 2015, Uniseed started its third and largest fund (Fund-3) with the addition of the University of Sydney and the CSIRO to the Universities of Queensland, Melbourne and NSW. This followed three high profile exits in the preceding 14 months (Fibrotech; Spinifex & Hatchtech). Each of the five partners committed $10 million over 10 years to the new fund (total fund $50 million).Uniseed’s partner research organisations spent nearly $4 billion on research, making up over 40% of the total research spend at 67 research organisations in Australia. Together, these organisations accounted for nearly 500 invention disclosures (34% of total) and 500 new registered IP rights filed (45% of total) over the same period(2013 National Survey of Research Commercialisation). Unlike private venture capital funds, Uniseed is dedicated to the needs of its research partners, and committed to servicing them consistently over the long term, irrespective of the short term conditions in external capital markets. It works in very close partnership with the research partner commercialisation companies and staff, providing a valuable adjunct to the capabilities these companies and staff provide. They in turn provide a best-practice commercialisation service tailored to their respective organisations. These companies are able to leverage to great effect the scale of operation and expertise of the Uniseed network.The fund is run with commercial discipline, ensuring independence and financial rigor in its investment decision-making processes. Success is measured by a balance of return on investment (including the flow of funds for research to further the commercialisation of intellectual property generated within the research partner catchments), the establishment of viable start-up companies, the generation of research income for research partners and the improvement of partner commercialisation processes.

Show more...

Investment focus

  • Biotechnology, Manufacturing, Health Care
  • Series A, Seed, Series B
  • Australia, United States, United Kingdom

Portfolio highlights

  • VeriQuantix — VeriQuantix was spun out of the University of Queensland. VeriQuantix is an Australian startup specializing in cybersecurity, focusing on quantum technology to enhance the security of optical fiber communication networks. Their core innovation, Quantum Link Verification (QLV), is designed to detect and alert network operators to physical tappingattempts and intercept cyber attacks on fiber optic networks. This technology leverages quantum principles, specifically entangled photons, to verify the trustworthiness of network links by ensuring that any unauthorized access disrupts photon entanglement and triggers immediate alerts.
  • Celosia Therapeutics — The Celosia Therapeutics approach is the result of advances in gene therapies and a better understanding of the molecular pathways that contribute to neurodegenerative diseases.
  • Kinoxis Therapeutics — Developing novel therapeutics for social dysfunction and substance use disorders.
Show all investments...
Investors by industry
Investors by country
VC (Venture Capital) Funds in Oceania by industry

Contact investors today

Find who invests in your industry, stage, and country in 5 minutes.

Find investors — It's Free!